EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose Optimization

Cong Chen, Mo Huang, Xuekui Zhang iD

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.70031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Cong Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Research Design, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Antineoplastic Agents. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs, Michael Smith Health Research BC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adaptive Phase 2/3 designs hold great promise in contemporary oncology drug development, especially when limited data from Phase 1 dose‐finding is insufficient for identifying an optimal dose. However, inconsistent results between Phase 2 and Phase 3 may raise regulatory and practical concerns. The imperfection in dose selection further complicates the issue. In this paper, we explicitly incorporate the concerns about inconsistency into the statistical analysis under three hypothesis testing strategies (conservative, aggressive, and neutral) by specifying an inconsistency cutoff and accounting for the probability of “picking‐the‐winner.” This investigation illustrates how to balance regulatory caution, sponsor interests, and practical considerations in adaptive Phase 2/3 designs with dose optimization, which paves the way for further research in a less explored area.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicAntineoplastic AgentsHumansDose-Response Relationship, DrugDrug DevelopmentData Interpretation, StatisticalModels, Statistical

Stichwörter der Autor:innen

adaptive designdose optimizationinconsistencyphase 2/3 trialseamless designtype I error control

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.
  • Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Department of Mathematics and Statistics, University of Victoria, Victoria, British Columbia, Canada.

ORCID-Profile: Xuekui Zhang

Förderung

  • Canada Research Chairs
  • Michael Smith Health Research BC

Zitieren

APA

Chen, C., Huang, M., & Zhang, X. (2025). Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose Optimization. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70031

Vancouver

Chen C, Huang M, Zhang X. Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose Optimization. Pharmaceutical Statistics. 2025. doi:10.1002/pst.70031

BibTeX
@article{Chen2025,
  author = {Chen, Cong and Huang, Mo and Zhang, Xuekui},
  title = {Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose Optimization},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.70031}
}
Kostenlos starten →